Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2010
10/12/2010CA2339761C Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
10/12/2010CA2329751C Substituted porphyrins
10/12/2010CA2327528C Recombinant virus expressing foreign dna encoding feline cd80, feline ctla-4 or feline cd86 and uses thereof
10/12/2010CA2320402C Modified ciliary neurotrophic factor, method of making and methods of use thereof
10/12/2010CA2307065C Modulating robo:ligand interactions
10/07/2010WO2010114181A1 Acrylamide compounds and the use thereof
10/07/2010WO2010113952A1 Muscarinic receptor antagonist
10/07/2010WO2010113942A1 Indolizine derivative and use thereof for medical purposes
10/07/2010WO2010113906A1 Met inhibitor comprising ephedrae herba
10/07/2010WO2010113860A1 Biphenyl-cyclic amine compound
10/07/2010WO2010113848A1 Isothiourea derivative or isourea derivative having bace1 inhibitory activity
10/07/2010WO2010113844A1 Rnai molecule for thymidylate synthase and use thereof
10/07/2010WO2010113834A1 Pyrimidine compound
10/07/2010WO2010113753A1 Prophylactic or therapeutic agent for retinal diseases and method for preventing or treating retinal diseases, each comprising jnk (c-jun n-terminal kinase)-inhibiting peptide, and use of the peptide
10/07/2010WO2010113507A1 Double-stranded molecule inhibiting the expression of gpc3
10/07/2010WO2010113498A1 Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient
10/07/2010WO2010113458A1 Method for manufacturing benzodiazepine derivative
10/07/2010WO2010113022A1 Plasminogen activator inhibitor-1 inhibitor
10/07/2010WO2010112615A1 Lysine derivatives functionalised with lipids
10/07/2010WO2010081862A3 Methods and preparations for protecting critically ill patients with a polyamine (e.g. spermine, spermidine)
10/07/2010WO2010075861A3 Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
10/07/2010WO2010027479A3 Mucosal delivery of therapeutic molecules, proteins, or particles coupled to ceramide lipids
10/07/2010US20100257634 Bioassay for gene silencing constructs
10/07/2010US20100256231 Novel derivatives of 3,3-diphenylpropylamines
10/07/2010US20100256230 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof
10/07/2010US20100256209 Compositions comprising ether compounds and pharmaceutical uses therefor
10/07/2010US20100256165 Large conductance calcium-activated k channel opener
10/07/2010US20100256119 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
10/07/2010US20100256118 Novel adenine compound and use thereof
10/07/2010US20100256111 Therapeutic agents useful for treating pain
10/07/2010US20100256093 Methods of and compositions for reducing cell death
10/07/2010US20100255537 Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptide and heterodimer thereof
10/07/2010US20100255501 Method of identifying a mhc class i restricted t cell response
10/07/2010US20100255092 Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release
10/07/2010US20100255088 Method for delivering a combination of resveratrol and aspirin for use in treatment and prevention of vascular disease
10/07/2010US20100255086 Method for oral mucosal absorption of acetyl salycylic acid
10/07/2010US20100255084 Medicinal melting capsules for oral mucosal absorption
10/07/2010US20100255050 Polyethylene Based Bioactive Agents
10/07/2010US20100254999 Eg-vegf nucleic acids and polypeptides and methods of use
10/07/2010US20100254962 Functional drink
10/07/2010US20100254916 Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof
10/07/2010US20100254904 Novel therapeutic delivery systems
10/07/2010US20100254902 Stabilization of radiopharmaceuticals
10/07/2010US20100254897 Seeds and Markers for Use in Imaging
10/07/2010DE102009046710A1 Use of licorice in a specific daily dose for oral treatment of headshaking in horses and for treating allergies
10/07/2010CA2757726A1 Acrylamide compounds and the use thereof
10/07/2010CA2757615A1 Plasminogen activator inhibitor-1 inhibitor
10/07/2010CA2757208A1 Method for manufacturing 1,5-benzodiazepine derivative
10/07/2010CA2757188A1 Pyrimidine compound
10/07/2010CA2756864A1 Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase)-inhibitory peptide, and use of the peptide
10/07/2010CA2755132A1 Indolizine derivative and use thereof for medical purposes
10/06/2010EP2236507A1 N-pyrazole-2-pyridinecarboxamide derivative
10/06/2010EP2236498A1 Phenyl acetamide derivative
10/06/2010EP2236152A1 Albumin fusion proteins
10/06/2010EP2236146A1 Composition for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving nutritional status during cancer chemotherapy
10/06/2010EP2236145A1 Pharmaceutical composition and combined agent
10/06/2010EP2236140A1 Regulation of phospholipase D activity
10/06/2010EP2236133A1 Pharmaceutical composition comprising fentanyl for the treatment of acute or breakthrough pain by sublingual administration
10/06/2010EP2236132A1 Pharmaceutical composition for the treatment of insomnia by sublingual administration
10/06/2010EP2236131A2 Compositions for manipulating the lifespan and stress response of cells and organisms
10/06/2010EP2235005A2 Azolylmethyloxiranes, use thereof and agents containing the same
10/06/2010EP1637132B1 External preparation for athlete´s foot treatment
10/06/2010EP1456650B1 Gfats as modifiers of the p53 pathway and methods of use
10/06/2010EP1451193B1 Podophyllotoxins as antiproliferative agents
10/06/2010EP1296951B1 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3'] bipyridinyl in pure crystalline form and process for synthesis
10/06/2010CN1951222B A health food for relieving fatigue and preparation method thereof
10/06/2010CN1784215B Melanogenesis promoter and melanogenesis promoter composition
10/06/2010CN1681508B Novel inhibitors of kinases
10/06/2010CN1606444B Inhibitors of human phosphatidyl-inositol 3-kinase delta
10/06/2010CN1514726B Pharmaceutical compositions
10/06/2010CN101855209A Alkylsulfone derivative
10/06/2010CN101855199A Tricyclic amide compound
10/06/2010CN101854943A Grifola frondosa extract and composition containing the same for promoting the production of hyaluronic acid (hyaluronan)
10/06/2010CN101854929A Novel preparation
10/06/2010CN101854911A Composition for external use
10/06/2010CN101851288A Analogs of parathyroid hormone
10/06/2010CN101851220A Isoprene flavonoid compound and application thereof
10/06/2010CN101851191A Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
10/06/2010CN101851173A Inhibitors of histone deacetylase
10/06/2010CN101850120A Solutions and methods for inhibition of pain, inflammation and cartilage degradation
10/06/2010CN101850075A Chinese medicine combination containing Herba elsholtziae
10/06/2010CN101849929A Medicine composition for treating psoriasis
10/06/2010CN101849924A Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
10/06/2010CN101849917A Orodispersible tablets containing fexofenadine
10/06/2010CN101323589B Preparation of novel compound and montelukast sodium
10/06/2010CN101120758B Liquid acidifier and preparation method
10/06/2010CN101006827B Combination formula of green feed additive and its processing method and application
10/05/2010US7807844 Reaction product of N-methylpyrrole, N-methylimidazole, 4-aminobutyric acid and B-alanine that can be folded into a U-shaped conformation at the gamma -aminobutyrate unit in a minor groove of a double helix region; conjugates with fluorescein isothiocyanate; antiproliferative agents; restenosis
10/05/2010US7807780 Multi-component biological transport systems
10/05/2010US7807701 Dibenzylamine compounds and pharmaceutical use thereof
10/05/2010US7807689 such as 2-{6-[3(R)-Amino-piperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl}-benzonitrile, used for the treatment of breast cancer and non-insulin depepndent diabetes
10/05/2010US7807688 corticotropin releasing factor receptor antagonists such as 8-(N-butyl-N-(2-butynyl)amino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine, used for the treatment of nervous system, psychological, eating, sleep, and gastrointestinal disorders
10/05/2010US7807678 Peptidomimetics of biologically active metallopeptides
10/05/2010US7807664 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof
10/05/2010US7807663 Therapeutic agents for diabetes
10/05/2010US7807659 5-Fluoro-4-oxo-3-[1-(substituted-carbonyl)-2-piperidinecarboxamido]-pentanoic acid derivatives such as [3S/R (2S)]-5-Fluoro-4-oxo-3-[1-(2-phenyl-thiazole-4-carbonyl)-2-piperidinecarboxamido]-pentanoic acid, used for the treatment of bone disorders, inflammatory, autoimmune and degenerative diseases
10/05/2010US7807658 Administering an optionally substituted 3-aminopropylphosphinic acid (3-amino-2-fluoropropyl)phosphinic acid, 3-amino-2-oxopropyl)phosphinic acid); irritable bowel syndrome
10/05/2010US7807654 Compositions and methods for treatment of mitochondrial diseases
10/05/2010US7807457 Recombinant viral and non-viral vectors containing the human urokinase plasminogen activator gene and its utilization in the treatment of various types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars
10/05/2010US7807430 Polypeptide of 250-419 contiguous amino acids of SEQ ID NO:1, where tyrosine 216 is phosphorylated and the polypeptide will crystallize; biological activity consisting of binding a GSK3 inhibitor and kinase activity; antidiabetic agents; Alzeimer's disease; antiinflammation agents; biological screening
1 ... 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 ... 1564